Nanoscope Therapeutics Inc.

📍 Dallas, United States🗓 Founded 2017👥 47 employees💰 Last funded Sep 2022
Biotechnology Research🌐 nanostherapeutics.com
Website LinkedIn
Nanoscope Therapeutics is advancing gene therapy using light-sensitive molecules and light-assisted gene delivery for giving sight to the millions of blind individuals suffering from retinal degenerative disease, for which no cure exists. Nanoscope is focused on proprietary ambient light-activated optogenetic therapy to restore vision in people suffering from various inherited retinal degenerative diseases including Retinitis Pigmentosa, Stargardt, and dry AMD. Genetic retinal degenerative diseases cause vision loss as cells of the retina gradually become dysfunctional. Nanoscope’s proprietary gene therapies correct the condition by delivering light-sensitive molecules, called Multi-Characteristic Opsins (MCO), into retinal cells.
4
Total investors
0
Early stage
3
Mid stage
0
Late stage
2017
Founded

Investors

4 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
3
India
1
Frequently asked questions
Who invested in Nanoscope Therapeutics Inc.?
Nanoscope Therapeutics Inc. has 4 investors on record on gritt.io, 3 mid-stage.
When did Nanoscope Therapeutics Inc. last raise funding?
The most recent investment in Nanoscope Therapeutics Inc. recorded on gritt.io was in September 2022.
When was Nanoscope Therapeutics Inc. founded?
Nanoscope Therapeutics Inc. was founded in 2017.
What industry is Nanoscope Therapeutics Inc. in?
Nanoscope Therapeutics Inc. operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Nanoscope Therapeutics Inc. based?
Nanoscope Therapeutics Inc. is headquartered in Dallas, United States.